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FOXO3aMitochondrial aldehyde dehydrogenase (ALDH2) is known to offer myocardial protection against stress condi-
tions including ischemia-reperfusion injury, alcoholism and diabetes mellitus although the precise mechanism
is unclear. This study was designed to evaluate the effect of ALDH2 on diabetes-induced myocardial injury with
a focus on autophagy. Wild-type FVB and ALDH2 transgenic mice were challenged with streptozotozin (STZ,
200 mg/kg, i.p.) for 3 months to induce experimental diabetic cardiomyopathy. Diabetes triggered cardiac re-
modeling and contractile dysfunction as evidenced by cardiac hypertrophy, decreased cell shortening and
prolonged relengthening duration, the effects of which were mitigated by ALDH2. Lectin staining displayed that
diabetes promoted cardiac hypertrophy, the effect of which was alleviated by ALDH2. Western blot analysis re-
vealed dampened autophagy protein markers including LC3B ratio and Atg7 along with upregulated p62 follow-
ing experimental diabetes, the effect of which was reconciled by ALDH2. Phosphorylation level of AMPK was
decreased and its downstream signaling molecule FOXO3a was upregulated in both diabetic cardiac tissue and
in H9C2 cells with high glucose exposure. All these effect were partly abolished by ALDH2 overexpression and
ALDH2 agonist Alda1. High glucose challenge dampened autophagy in H9C2 cells as evidenced by enhanced
p62 levels and decreased levels of Atg7 and LC3B, the effect of which was alleviated by the ALDH2 activator
Alda-1. High glucose-induced cell death and apoptosis were reversed by Alda-1. The autophagy inhibitor 3-MA
and the AMPK inhibitor compound C mitigated Alda-1-offered beneﬁcial effect whereas the autophagy inducer
rapamycin mimicked or exacerbated high glucose-induced cell injury. Moreover, compound C nulliﬁed Alda-1-
induced protection against STZ-induced changes in autophagy and function. Our results suggested that ALDH2
protects against diabetes-induced myocardial dysfunction possibly through an AMPK -dependent regulation of
autophagy. This article is part of a Special Issue entitled: Autophagy and protein quality control in cardiometabolic
diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The mitochondrial chaperon aldehyde dehydrogenase 2 (ALDH2) is
one of the principle enzymes responsible for the metabolism ory and protein quality control in
iology, Xijing Hospital, Fourth
+86 84775183; fax: +86 29
29 84771170.
. Zhang),wanghc@fmmu.edu.cndetoxiﬁcation of acetaldehyde and other toxic aldehydes [1–4]. While
the mitochondrial enzyme has been well known for its permissive role
in ethanol and acetaldehyde metabolism [4,5], a rather unique protec-
tive role has been unveiled recently for ALDH2 in diabetes mellitus-
induced myocardial anomalies [6–8]. This is consistent with the beneﬁ-
cial role of ALDH2 in the combat against ischemia and reperfusion as
well as arrhythmic myocardial injuries [2,3,9]. These observations
have collectively favored an indispensible role for this mitochondrial
enzyme in the governance of cardiac homeostasis. Nonetheless, the pre-
cise mechanism of action behind ALDH2-offered beneﬁcial impact
against cardiac anomalies in the face of diabetes remains largely elusive.
Autophagy is essential to maintain energy homeostasis and cell sur-
vival under both physiological and pathological conditions [10]. Ample
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tophagy in the regulation of cardiac homeostasis [10–13]. For example,
autophagy may be initiated to facilitate the cellular self-repair machin-
ery in response to cardiovascular anomalies including heart failure and
ischemic injury [14–17]. Our recent ﬁnding suggested a beneﬁcial effect
for ALDH2 against diabetes-induced myocardial injury [18] although it
remains elusive with regards to a possible role for autophagy in the
ALDH2-offered protection against diabetic cardiomyopathy.
Given the indispensible role for autophagy in cell injury and survival
undermyopathic conditions [16], the present studywas designed to ex-
amine the role for autophagy in ALDH2-offered beneﬁcial effect against
diabetic myopathic injury using a murine model of ALDH2 overexpres-
sion. Cell signalingpathwayswere examinedwith a focus on autophagy,
in particular AMP-dependent protein kinase (AMPK), the main kinase
governing myocardial survival and function [3]. Activation of AMPK
and the AMPK downstream signaling molecule unc-51-like kinase
(ULK1) may promote whereas activation of the AMPK downstream sig-
nal FOXO3a (phosphorylation) may suppress autophagy [19,20]. In ad-
dition, AMPK has been shown to facilitate autophagy through its
inhibitory effect on FOXO3a and phosphorylation of ULK1 [19,21–23].Fig. 1. Cardiomyocyte contractile properties in FVB and ALDH2 transgenic mice treatedwith or
length); (C) maximal velocity of shortening (+dL/dt); (D) maximal velocity of relengthening
n = 103 cells from four mice per group.*P b 0.05 vs. FVB group; #P b 0.05 vs. FVB-STZ group.To this end, the aim of this study was to examine (1) whether ALDH2
transgene offers protection against diabetic cardiomyopathy associated
with changes in myocardial autophagy; (2) whether in vitro incubation
of high glucose alters autophagy in H9C2 cells, and (3) the regulatory
mechanisms involved in diabetes or high glucose-induced changes in
autophagy with a focus on AMPK.
2. Methods
2.1. Experimental animals and experimental diabetes
All experimental procedures were approved by the University of
Wyoming Animal Care and Use Committee. Characterization of ALDH2
transgenic mice using the chicken β-actin promoter was described in
detail [7]. All mice were housed in a temperature-controlled room
under a 12 hr/12 hr-light/dark cycle with access to water and food ad
libitum. Fivemonth-oldmale FVB (used aswild-type) and ALDH2 trans-
genic mice were injected intraperitoneally with streptozotocin (STZ,
200 mg/kg) and were maintained for another 3 months. All mice
were allowed free access to standard laboratory chow and tap waterwithout streptozotocin. (A) Resting cell length; (B) peak shortening (PS, normalized to cell
(−dL/dt); (E) time-to-PS (TPS) and (F) time-to-90% relengthening (TR90). Mean ± SEM,
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(overnight) and postprandial (2 h after re-feeding following the over-
night fasting) blood glucose levels were determined using an Accu-
ChekII glucose analyzer [1]. FVB andALDH2 transgenicmicewith fasting
blood glucose levels N13 mMwere deemed diabetic [24].
2.2. Isolation of murine cardiomyocytes
After an intraperitoneal administration of sedative (ketamine
80 mg/kg and xylazine 12 mg/kg), hearts were removed and were
digested with Liberase Blendzyme 4 (Hoffmann-La Roche Inc.,
Indianapolis, IN, USA) for 20 min. Cardiomyocyte yield was approxi-
mately 75% which was unaffected by STZ treatment or ALDH2 overex-
pression. Only rod-shaped myocytes with clear edges were selected
for the mechanical study [25].
2.3. Cell shortening and relengthening
Themechanical properties of cardiomyocyteswere assessed using an
IonOptix™ Soft-Edge system (IonOptix Corporation, Milton, MA, USA)
[7]. Myocytes were placed in a Warner chamber mounted on the stage
of an inverted microscope (Olympus, IX-70, Olympus Corporation,
Tokyo, Japan) and superfused (approximately 1 ml/min at 25 °C) with
a buffer containing (inmM):131NaCl, 4 KCl, 1 CaCl2, 1MgCl2, 10 glucose
and10 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), at
pH 7.4. The cells were ﬁeld stimulated with at a frequency of 0.5 Hz for
3 ms using a pair of platinum wires placed on opposite sides of the
chamber connected to a FHC stimulator (Brunswick, NE, USA). The
myocyte being studied was displayed on the computer monitor using
an IonOptix MyoCam camera. IonOptix SoftEdge software was used
to capture changes in cell length during the cell shortening and
relengthening. Cell shortening and relengthening were assessed using
the following indices: peak shortening (PS), the peak ventricular
contractility; time-to-PS (TPS; contraction duration) and time-to-90%Fig. 2. Cardiomyocyte intracellular Ca2+ handling properties in FVB and ALDH2 transgenic mi
(B) peak FFI; (C) electrically-stimulated rise in FFI (ΔFFI); (D) intracellular Ca2+ decay rate (si
group; #P b 0.05 vs. FVB-STZ group.relengthening (TR90), the cardiomyocyte relaxation duration; andmax-
imal velocities of shortening (+dL/dt) and relengthening (−dL/dt), the
maximal velocities of ventricular pressure rise and fall [25].
2.4. Intracellular Ca2+ transient measurement
Myocytes were loaded with fura-2-acetoxymethyl ester (0.5 μM)
for 10 min and ﬂuorescence measurements were recorded with a
dual-excitation ﬂuorescence photomultiplier system (IonOptix).
Cardiomyocytes were placed on anOlympus IX-70 invertedmicroscope
and imaged through a Fluor ×40 oil objective. Cells were exposed to
light emitted by a 75 W lamp and passed through either a 360 or a
380 nm ﬁlter, while being stimulated to contract at 0.5 Hz. Fluorescence
emissionswere detected between 480 and 520 nmby a photomultiplier
tube after ﬁrst illuminating the cells at 360 nm for 0.5 s then at 380 nm
for the duration of the recording protocol (333 Hz sampling rate). The
360 nm excitation scan was repeated at the end of the protocol and
qualitative changes in intracellular Ca2+ concentration were inferred
from the ratio of fura-2 ﬂuorescence intensity (FFI) at the two wave-
lengths (360 and 380 nm). Fluorescence decay time was measured as
an indication of the intracellular Ca2+ clearing rate. Both single- and
bi-exponential curve ﬁt programswere applied to calculate the intracel-
lular Ca2+ decay constant [7].
2.5. Histological examination
Following anesthesia, hearts were excised and immediately
placed in 10% neutral-buffered formalin at room temperature for 24 h
after a brief rinse with PBS. The specimen were embedded in parafﬁn,
cut in 5 μm sections and stained with FITC-conjugated wheat germ
agglutinin (lectin). Heart sections were stained with for lectin gross
morphology analysis. Cardiomyocyte cross-sectional areas were calcu-
lated on a digital microscope (×400) using Image J (version1.34S)
software.ce treated with or without streptozotocin. (A) Resting fura-2 ﬂuorescence intensity (FFI);
ngle exponential); mean ± SEM, n= 70 cells from four mice per group. *P b 0.05 vs. FVB
Fig. 3.Histological analysis in hearts from FVB and ALDH2 transgenic mice treatedwith or
without streptozotocin. A–D: Representative lectin stainingmicrographs displaying trans-
verse myocardial section (×400); (A): FVB; (B): FVB-STZ; (C): ALDH2; (D): ALDH2-STZ;
(E): quantitative analysis of cross section area; mean ± SEM, n= 200–245 cells from 4
mice per group *p b 0.05 vs. FVB group, #p b 0.05 vs. FVB-STZ group.
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H9C2 cells, a permanent cell line derived from embryonic BD1X rat
heart tissue, were grown in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS)
(Gibco, Grand Island, NY, USA) and 1% penicillin and streptomycin. All
cells were maintained in 95% air and 5% CO2 at 37 °C. The medium
was replaced every 2–3 days. In the vitro study, H9C2 myoblast cells
were treated with normal (NG, 5.5 mM) and high doses (HG, 30 mM)
[26] of glucose in the absence or presence of the ALDH2 activator
Alda-1 (20 μM) [27] for 48 h. To evaluatewhether and howhigh glucose
could affect autophagic activity in cardiomyocytes, H9C2 cells were
treatedwith high glucose in the absence or presence of Alda-1 or the au-
tophagy inhibitor 3-methyladenine (3-MA, 10mM) [28] or the autoph-
agy inducer rapamycin (Rapa, 100 nM) [3] or the AMPK inhibitor
compound C (CC, 10 mM) [29] prior to assessment of their mechanical
and biochemical properties.
2.7. Cell viability MTT assay
[3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide]
(MTT) assay is based on the transformation of the tetrazolium salt
MTT by active mitochondria to an insoluble formazan salt. H9C2 cells
were plated in microtiter plate at a density of 3 × 105 cells/ml. MTT
was added to each well with a ﬁnal concentration of 0.5 mg/ml, and
the plates were incubated for 2 h at 37 °C. The formazan crystals in
eachwell were dissolved in dimethyl sulfoxide (150 μl/well). Formazan
was quantiﬁed spectroscopically at 560 nm using a SpectraMax® 190
spectrophotometer [30].
2.8. TUNEL assay
TUNEL staining of myonuclei positive for DNA strand breaks was de-
termined using a ﬂuorescence detection kit (Roche, Indianapolis, IN)
and ﬂuorescence microscopy. Brieﬂy, parafﬁn-embedded sections (5
μm) were deparafﬁnized and rehydrated. The sections were then incu-
bated with Proteinase K solution at room temperature for 30 min.
TUNEL reactionmixture containing terminal deoxynucleotidyl transfer-
ase (TdT), ﬂuorescein-dUTP was added to the sections in 50-μl drops
and incubated for 60 min at 37 °C in a humidiﬁed chamber in the
dark. The sectionswere rinsed three times in PBS for 5min each. Follow-
ing embedding, sectionswere visualizedwith anOlympus BX-51micro-
scope equipped with an Olympus MaguaFire SP digital camera. DNase I
and label solutionwere used as positive and negative controls. To deter-
mine the percentage of apoptotic cells, micrographs of TUNEL-positive
and DAPI-stained nuclei were captured using an Olympus ﬂuorescence
microscope and counted using the ImageJ software (ImageJ version
1.43r; NIH) from 15 random ﬁelds at 400× magniﬁcation. At least one
hundred cells were counted in each ﬁeld [31].
2.9. Measurement of mitochondrial membrane potential (ΔΨm)
H9C2 cells in 35 mm2 dishes were suspended in HEPES saline
buffer and themitochondrial membrane potential (ΔΨm)was detected
as previously described [6]. Then they were incubated with JC-1 (5 μM)
in growth medium for 10 min at 37 °C. The cultures were washed
three times using fresh growth medium. Fluorescence was examined
with a confocal laser scanning microscope (Spectra MaxGeminiXS,
spectra Max, Atlanta, GA, USA) at an excitation wavelength of 490 nm.
Green ﬂuorescence represented themonomeric form of JC-1, appearing
in the cytosol after mitochondrial membrane depolarization. Red
emission represents a potential-dependent aggregation in the mito-
chondria, reﬂecting mitochondrial membrane potential measure-
ment. Fluorescence of each sample was read at an excitation
wavelength of 490 nm and an emission wavelength of 530 (green)
and 590 (red) nm. Results in ﬂuorescence intensity were expressed as590-to-530-nm emission ratio. The mitochondrial uncoupler carbonyl
cyanide m-cholorophenylhydrazone (CCCP, 10 μmol/l) was used as a
positive control for mitochondrial membrane potential measurement.2.10. LC3B-GFP-adenovirus production, infection, and quantiﬁcation in
H9C2 cells
H9c2 cells were transfected with adenoviruses expressing GFP-LC3
fusion protein for 6 h. Cells transfected with GFP-LC3 adenovirus were
then incubatedwith orwithout HG (30mM) in the absence or presence
of the ALDH2 activator Alda1 (20 μM). To examine the role for AMPK in
high glucose and ALDH2 activation induced autophagy response, the
AMPK inhibitor compound C (5 μM), the autophagy inhibitor 3-MA
(10 mM) and the autophagy inducer rapamycin (100 nM) were used.
To evaluate the autophagsome formation, the GFP-LC3-positive cells
were quantitated in H9c2 cells pre-incubated with compound C, 3-MA
or rapamycin prior to HG treatment. Cells were visualized using a
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showing GFP-LC3 puncta (N10 dots/cell) were scored as described.2.11. Western blot analysis
Proteins were extracted from H9C2 cells as described [32].
Membrane protein samples were subjected to PAGE, transferred to
the polyvinylidene diﬂuoride membrane. The membranes were
blocked with 5% milk and incubated overnight with anti-p62 (5114),
anti-ATG7 (2631), anti-LC3B (3868), anti-AMPK (Thr172), anti-
phosphorylated(p)-AMPK, anti-Foxo3a, anti-p-Foxo3a (Ser253), anti-
ULK1, anti-p-ULK1 (Ser757) and anti-glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; loading control). Antibodies for P62, ATG7,
LC3B, AMPK and p-AMPK were purchased from Cell Signaling Technol-
ogy (Danvers, MA, USA, 1:1000) while antibody for FOXO3a and
p-FOXO3a were purchased from Bio-word Technology (SH, China,
1:1000). The membranes were incubated with horseradish peroxidase-Fig. 4.Western blot analysis of the autophagymarker p62, LC3 and Atg7 in themyocardium from
blots of p62, LC3, Atg7 and GAPDH (loading control) using speciﬁc antibodies; B: p62; C: Atg7
were normalized to the loading control GAPDH. Mean ± SEM, n= 5–6 mice per group, *p b 0coupled secondary antibodies. After immune-blotting, ﬁlms were
scanned and detected by the luminescence method [33].
2.12. Data analysis
Data were presented as the means ± SEM. Differences between ex-
perimental groups were examined by one-way analysis of variance
(ANOVA), followed by Tukey's test for post hoc test (Graph-Pad4.0,
GraphPad Software, La Jolla, CA, USA). Values of P b 0.05 were consid-
ered statistically signiﬁcant.
3. Results
3.1. Effect of ALDH2 on diabetes-induced changes in cardiomyocyte
contractile function
Neither experimental diabetes nor ALDH2 transgene affected resting
cell length, as shown in Fig. 1 Experimental diabetes signiﬁcantlyFVB and ALDH2mice treatedwith orwithout streptozotocin (STZ). A: Representative gel
; D: LC3II-to-GAPDH ratio; E: LC3I-to-GAPDH ratio; and F: LC3II-to-LC3I ratio. All proteins
.05 vs. FVB group, #p b 0.05 vs. FVB-STZ group.
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(±dL/dt) as well as prolonged TR90 without affecting TPS, reminiscent
of earlier ﬁndings [18,34]. Importantly, ALDH2 transgene ablated
diabetes-induced mechanical abnormalities without eliciting any nota-
ble effect by itself.
3.2. Effect of ALDH2 on diabetes-induced changes in intracellular
Ca2+ handling
To explore the potential mechanism of action involved in the
ALDH2-elicited beneﬁcial effects against experimental diabetes, fura-2
ﬂuorescence was employed to monitor intracellular Ca2+ homeostasis.
Data presented in Fig. 2 reveal that diabetes signiﬁcantly depressed
intracellular Ca2+ rise in response to electrical stimulus (ΔFFI) and
reduced intracellular Ca2+ decay rate (single-exponential curve ﬁt)Fig. 5. Phosphorylation of AMPK and Foxo3a in themyocardium from FVB and ALDH2mice trea
ylated AMPK (GAPDH as loading control); B: pAMPK-to-GAPDH ratio; C: AMPK-to-GAPDH rat
Foxo3a (GAPDH as loading control); F: pFoxo3a -to-GAPDH ratio; G: Foxo3a -to-GAPDH ratio
group, #p b 0.05 vs. FVB-STZ group.along with unchanged baseline intracellular Ca2+ in cardiomyocytes,
the effect of which was reconciled by ALDH2. ALDH2 transgene itself
failed to affect these intracellular Ca2+ indices tested.3.3. Effect of ALDH2 on diabetes-induced changes in the cardiomyocyte
cross-sectional area
To assess the impact of ALDH2 overexpression onmyocardial histol-
ogy in diabetic myocardiopathy, the cardiomyocyte cross-sectional area
was examined. Findings from the FITC-conjugated wheat germ staining
sections revealed increased cardiomyocyte area following experimental
type I diabetes. ALDH2 transgene itself did not affect cardiomyocyte
size, while the experimental diabetes-induced change in cardiomyocyte
size was effectively ablated by ALDH2 overexpression (Fig. 3).tedwith orwithout streptozotocin (STZ). A: Representative gel blots of pan and phosphor-
io; and D: pAMPK-to-AMPK ratio. E: Representative gel blots of pan and phosphorylated
; H: pFoxo3a -to- Foxo3a ratio. Mean ± SEM, n= 6–8 mice per group, *p b 0.05 vs. FVB
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autophagy regulatory signaling
To explore the potentialmechanismof action involved in the ALDH2-
elicited beneﬁcial effects against experimental diabetes, autophagy
and autophagy regulatory signaling was examined using Western blot
analysis. Our results revealed depressed myocardial autophagy under
experimental diabetes as evidenced by decreased levels of LC3II-to-
LC3I ratio and Atg7. As shown in Fig. 4, although ALDH2 overexpression
itself failed to alter these autophagy protein markers, it prevented
diabetes-induced loss in autophagy. Further analysis of autophagy
regulatory signaling depicted that ALDH2 partly reversed downregula-
tion of phosphorylated AMPK induced by high glucose, as well as upreg-
ulated phosphorylation of FoxO3a (Fig. 5).
3.5. Effects of Alda1 and AMPK on apoptosis and cell viability with high
glucose exposure
To assesswhether ALDH2 activation alters high glucose-induced ap-
optosis, TUNEL staining was used to examine apoptosis in H9C2 myo-
blasts. Fig. 6 (panels A–O) indicated the TUNEL-positive cells were
more abundant in the HG group, the effect of which was signiﬁcantly
attenuated by the ALDH2 activator Alda-1. Alda-1 itself did not triggerFig. 6. Cell survival and apoptosis of H9C2 cells incubated in high or low glucose. All nuclei w
L (HG + Alda1-3-MA), M (HG + Rapa), and N (HG + Alda1 + CC). TUNEL-positive nucle
D (HG + Alda1), E (HG + Alda1-3-MA), F (HG + Rapa), and G (HG + Alda1 + CC). Original
analysis of cardiomyocyte cell survival usingMTT.Mean± SEM, n=12ﬁelds per group for pan
HG group, &P b 0.05 vs. HG + Alda-1 group.apoptosis under normal glucose culture. Interestingly, both 3-MA and
compound C effectively mitigated Alda-1-offered protection against
high glucose-induced cell death. Likewise, the autophagy inducer
rapamycin mimicked Alda-1-induced beneﬁcial effect against high glu-
cose. The same trend of cell viabilitywithMTTdatawere shown in Fig. 6
(panel P). In brief, 3-MA and compound C signiﬁcantly alleviated the
protective effect of Alda-1 in high glucose-decreased cell viability. Our
result revealed that high glucose signiﬁcantly increased cardiomyocyte
apoptosis and decreased cell viability. These ﬁndings indicated that
Alda-1 protects against high glucose-induced cell apoptosis and cell
viability decrease in H9C2 cells.
3.6. Effects of Alda1 and AMPK on high glucose-induced
mitochondrial damage
Wewent on to examine the mechanism(s) of action behind ALDH2-
elicited protection against high glucose-induced cardiomyocyte me-
chanical dysfunction;H9C2myoblastswere examined formitochondrial
integrity, using JC-1 ﬂuorescencemicroscopy. The result shown in Fig. 7
and ﬂuorescence data displayed in Fig. 7 (panels A and Y) revealed mi-
tochondrial membrane potential in the HG group, the effect of which
was reconciled by Alda-1. However, Alda-1 failed to affectmitochondrial
membrane potential under normal glucose incubation. 3-MA andere stained with DAPI (blue) in panels H (NG), I (HG), J (NG + Alda1), K (HG + Alda1),
i were visualized with ﬂuorescein (green) in panels A (NG), B (HG), C (NG + Alda1),
magniﬁcation = 400×. Quantiﬁed data of apoptosis are shown in panel O; J: quantitative
el O, n=15wells per group for panel P, *P b 0.05 vs.NG orNG+Alda-1 group, #P b 0.05 vs.
Fig. 7. Effect of Alda-1 and high glucose on H9C2 mitochondrial membrane potential (MMP) using JC-1 ﬂuorescence. A–X in panel I: Representative JC-1 ﬂuorochrome images depicting
MMP inH9C2 cells groups. Themitochondrial uncoupler carbonyl cyanidem-chlorophenylhydrazone (CCCP) (10 μM)was used as a positive control; Panel II: Quantitative analysis of mi-
tochondrialmembranepotential (ratio of the redﬂuorescenceobtained at 590nmto the greenﬂuorescence at 530 nm). (Scale bar=20 μM).Datawere expressed as themean+SEM, and
analyzed by one-way ANOVA (n= 4 isolation per group). *P b 0.05 vs. NG or NG + Alda-1 group, #P b 0.05 vs. HG group, &P b 0.05 vs. HG + Alda-1 group.
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membrane potential. On the other hand, rapamycin effectively en-
hanced the ATP content and mitochondrial membrane potential in a
manner reminiscent to Alda-1. These ﬁndings indicate a corroborative
role of mitochondrial function in ALDH2-offered cardio-protection
against high glucose-induced cardiomyocyte injury.
3.7. Effect of Alda-1 and AMPK on high glucose-induced change in
autophagy protein markers
To investigate the role for AMPK in HG-induced suppression of au-
tophagy, H9c2myoblasts were transfected with an adenovirus express-
ing GFP-LC3 fusion protein for 24 h prior to the exposure to HG in the
absence or presence of the autophagy inhibitor 3-MA or the AMPK in-
hibitor compound C. Evaluation of autophagosome formation using
GFP-LC3 puncta revealed that either 3-MA (10 mM) or compound C
(5 μM) negated Alda-1 (20 μM)-induced rise in GFP-LC3 puncta in the
face of HG incubation. The autophagy inducer rapamycin promoted
GFP-LC3 puncta formation under HG environment. These ﬁndings fa-
vored a role for AMPK activation in Alda-1-induced restoration of au-
tophagy under HG incubation (Fig. 8). Our data also revealed that highglucose induced downregulation of autophagic markers including
Atg7 and LC3B conversion as well as upregulation of p62, the effects of
which were alleviated by Alda-1 (Fig. 9B–D). Rapamycin mimicked
the protective effect of Alda1 in high glucose-induced autophagy. As
shown in Fig. 9, Alda-1 itself failed to affect levels of these proteins of in-
terest under normal glucose culture. Nonetheless, high glucose effec-
tively decreased the levels of autophagy, the effect of which was
abolished by Alda-1. Autophagy inhibitor 3-MA and AMPK inhibitor
Compound C reversed the autophagy recovery of Alda-1 following
high glucose exposure.
3.8. Effect of Alda-1 on high glucose-induced change in the levels of AMPK,
FOXO3a and ULK1
To examine the potential signaling pathways involved in high glu-
cose and/or ALDH2-elicited cardiac autophagic and mechanical re-
sponse, we examined levels of the cardiac energy fuel sensor AMPK,
and its downstream signaling molecules FOXO3a and ULK1. Our results
indicated that high glucose treatment markedly suppressed the phos-
phorylation of AMPK and ULK1 with unchanged expression of total
AMPK in H9C2 myoblasts (Fig. 10B and D). Otherwise, high glucose
Fig. 8. Effect of Alda-1, 3-MA and compound C on high glucose-induced change in autophagosome formation H9c2 myoblasts. Representative images of GFP depicting GFP-LC3 puncta
in H9c2 cells shown in panel (A); and (B) percentage of cells with autophagosomes. Cells with 10 or more punctate spots were scored as positive for autophagosomes. Mean ± SEM,
n = 200–300 cells per group, *P b 0.05 vs. NG or NG + Alda-1 group, #P b 0.05 vs. HG group, &P b 0.05 vs. HG + Alda-1 group.
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FOXO3a (Fig. 10C). Alda-1 itself failed to affect the phosphorylation of
AMPK, FOXO3a and ULK1, and it effectively reconciled high glucose-
induced change in phosphorylated of AMPK, ULK1 and FOXO3a. Both
3-MA and compound C reversed the protein change effects of Alda-1
with high glucose treatment. The changes of AMPK, ULK1 and FOXO3a
phosphorylation induced by high glucosewere attenuated by rapmycin,
the effect of which was similar to that of Alda1.
4. Discussion
Themitochondrial enzymeALDH2has been shown to rescue against
diabetic-induced cardiomyopathy injury [18]. Data from our present
study provided, for the ﬁrst time, compelling evidence that ALDH2 ex-
erts protective effects against diabetes-induced myocardial changes
through facilitating AMPK-dependent autophagy. Our data indicated
that diabetes or high glucose-induced alterations in cardiac mechanical
and autophagic responses may be associated with dampened and ele-
vated, phosphorylation of AMPK and FOXO3a, respectively. ALDH2
and its agonist Alda-1 are likely to offer protection by reversing diabetes
or high glucose-induced changes in AMPK and FOXO3a signaling, en
route to improved autophagy, cardiac geometry and function. Further-
more, possible involvement of autophagy in high glucose-inducedcardiomyocyte dysfunctionwas conﬁrmed by pharmacologicalmodula-
tion of autophagy using 3-MA and rapamycin. The ALDH2-offered pro-
tection was recapitulated by Alda-1 and rapamycin, testifying the
therapeutic value of this mitochondrial enzyme. Interestingly, the
Alda-1-elicited beneﬁcial effect against high glucose was cancelled
off by the AMPK inhibitor compound C and the autophagy inhibitor
3-MA. Taken together, these ﬁndings revealed that ALDH2 may be pro-
tective against high glucose-induced cardiac toxicity through promoting
the AMPK-dependent autophagy en route to improved cardiomyocyte
mechanical function. This ﬁnding is further supported by the fact that
3-MA negated alda-1-offered beneﬁcial response against high glucose-
induced apoptosis. This is in line with the beneﬁcial effect of rapamycin
against high glucose-induced cardiomyocyte cell death. Overall, these
observations suggest that induction of autophagy may be a potential
therapeutic strategy for hyperglycemic cardiotoxicity (Fig. 11).
Our data revealed that high glucose exposure triggered cardiomyo-
cyte contractile defects including reduced PS and ±dL/dt; and
prolonged TR90 in cardiomyocytes from diabetic mice. These ﬁndings
are reminiscent to previous reports [35]. These ﬁndings are consistent
with the previous notion ofmyopathic anomalies characterized by com-
promised myocardial contractility in diabetes [24,34,36]. Reduced con-
tractility and prolonged duration of systole as well as diastole are
hallmarks of diabetic cardiomyopathy [35]. Several mechanisms may
Fig. 9. Effect of Alda-1, 3-MA, compound C on high glucose-induced change in autophagy markers. (A) Representative gel bolts depicting respective protein expression using speciﬁc
antibodies; (B) p62; (C) Atg7; (D) LC3-II to LC3-I ratio; mean + SEM, n= 5, *P b 0.05 vs. NG or NG + Alda-1 group, #P b 0.05 vs. HG group, &P b 0.05 vs. HG+ Alda-1 group.
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intracellular Ca2+ homeostasis and oxidative stress [36]. A number of
theories have been put forward regarding high glucose-induced cardiac
toxicity including lipid peroxidation, oxidative damage [37], mitochon-
drial dysfunction [6,38], and altered membrane properties [38]. To
expand on this list, intracellular Ca2+ homeostasis was interrupted
in response to hyperglycemic challenge manifested as depressed intra-
cellular Ca2+ rise in response to electrical stimulus (ΔFFI) and reduced
intracellular Ca2+ decay, suggesting an essential role of intracellular
Ca2+ dysregulation in diabetes-induced toxicity in the heart. In our
study, the impaired intracellular Ca2+ handling [reduced intracellular
Ca2+ clearance and intracellular Ca2+ rise (ΔFFI)] may likely under-
score the reduced PS, maximal velocity of shortening and relengthening
observed in STZ-induced diabeticmouse hearts. The fact that theALDH2
transgene reconciled STZ-induced intracellular Ca2+ mishandling
favors a possible role of intracellular Ca2+ homeostasis in diabetes-
induced myocardial dysfunction and ALDH2-offered protection, some-
what reminiscent of the beneﬁcial role of mitochondrial protection
against diabetes-induced myocardial dysfunction [39,40]. Our ﬁndings
revealed a loss of mitochondrial membrane potential, overt apoptosis
(demonstrated by TUNEL) and decrease of cell survival (indicated by
MTT) along with downregulated levels of autophagy in high glucose-
induced myocardial damaged, suggesting a corroborative role of mito-
chondrial dysfunction,apoptosis and cell death in diabetic cardiomyop-
athy [41], as reported previously [39,42]. In addition, our observations
show that ALDH2 plays an important role in the maintenance of intra-
cellular Ca2+ homeostasis in diabetes-induced cardiac contractile dys-
function and ALDH2-offered protection. However, little is known withregard to the precise mechanism involved in ALDH2-offered protection
against hyperglycemic cardiotoxicity. The present study revealed that
ALDH2 counteracts cardiac toxicity of hyperglycemia (cardiac function
and intracellular Ca2+ handling) possibly associated with regulation of
autophagy. This is supported by the ﬁndings from the pharmacological
regulators of autophagy and the ALDH2 agonist Alda-1. In particular,
the autophagy inhibitor 3-MA and the AMPK inhibitor compound C
(which is expected to suppress autophagy [43]) mitigated whereas
the autophagy inducer rapamycin mimicked Alda-1-offered protection
against high glucose-induced cardiomyocyte toxicity. Static levels of
Atg7 and LC3B II-to-LC3B I ratio may render possible misinterpretation
for autophagy as Atg7 and LC3B II levels may increase, decrease or re-
main unchanged in the setting of autophagy induction depending on
the status of lysosomal degradation (namely autophagy ﬂux) [44]. The
elevated expression in p62 following experimental diabetes indicated
the possible presence of impaired autophagy ﬂux. Moreover, our data
depicted that Alda-1 reversed high glucose-induced suppression in au-
tophagy, in line with its beneﬁcial effect against cardiac mechanical de-
fect. Theseﬁndings suggest that Alda-1may upset high glucose-induced
autophagy. It is noteworthy that inhibition of autophagy has been noted
to be responsible for ALDH2-offered cardioprotective actions in a num-
ber of stress conditions such as ischemia-perfusion injury, alcoholic car-
diomyopathy and dilated cardiomyopathy [3,45,46]. Although the
disparity in ALDH2-triggered autophagy response between our present
work and the aforementioned earlier reports remains unclear at this
point, it is plausible to speculate that ALDH2 may turn on multiple cell
signaling regulatory machineries in diabetes to offer a synchronized
action in autophagy. In the event of chronically developed diabetic
Fig. 10. Effect of Alda-1 on high glucose-induced change in the expression of pan and phosphorylated AMPK, FOXO3a and ULK1 in H9C2 cells. (A) Representative gel bolts depicting
respective protein expression using speciﬁc antibodies; (B) pAMPK-to-AMPK ratio; (C) pFoxo3a -to- Foxo3a ratio; (D) pULK1-to-ULK1 ratio. Mean + SEM, n= 5, *P b 0.05 vs. NG or
NG + Alda-1 group, #P b 0.05 vs. HG group, &P b 0.05 vs. HG + Alda-1 group.
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ALDH2 may upregulate autophagy en route to preservation of cardiac
homeostasis.Fig. 11. Schematic diagram depicting possiblemechanisms involved in protective effect of
ALDH2 in high glucose-induced changes in cardiac contractile and geometry.Results from our study revealed suppressed autophagy in STZ-
induced type 1 diabetes model. Nonetheless, it remains controversial
with regard to the precise role of autophagy in the onset and progres-
sion of diabetic cardiomyopathy. In our current study, STZ-induced dia-
betic cardiomyopathy decreased AMPK activity and subsequently
suppression of cardiac autophagy, in line with the ﬁnding from OVE26
type 1 diabetic mice [47]. A role for autophagy seems to be more com-
plex in type 2 diabetes-induced cardiomyopathy. Cardiomyocytes
from type 2 diabetic db/dbmice exhibited blunted autophagic response
[48], while fructose feeding promoted myocardial autophagy in con-
junction with insulin resistance [49]. Although data from our present
study favor the notion that ALDH2mitigated high glucose-induced sup-
pression in autophagy (elevated levels of p62 as well as decreased Atg7
and LC3B II levels), the precise mechanism behind the mitochondrial
enzyme-offered protection against high glucose-induced autophagy
still remains elusive. It is plausible to speculate that ALDH2 promotes
autophagy (whichwas suppressed by diabetes and high glucose) via ac-
tivation of AMPK. This is supported by our ﬁndings that ALDH2 and
Alda-1 nulliﬁed high glucose-induced AMPK and ULK1 inhibition as
well as FOXO3a activation. AMPK is an essential regulator for autopha-
gy, cell survival, energy metabolism and contractile function in the
heart [50–52]. Consistently, data from our current study also revealed
suppressed AMPK phosphorylation in conjunction with cardiac dys-
function and autophagy against high glucose cardiotoxicity. In addition,
AMPK is an essential regulator for myocardial survival, contractile func-
tion and autophagy either independently or indirectly through FOXO3a
[35,36]. Therefore, FOXO3a may serve as a mediator for ALDH2
and Alda-1-mediated autophagic regulation through AMPK signaling.
330 Y. Guo et al. / Biochimica et Biophysica Acta 1852 (2015) 319–331ULK1, a key initiator of autophagic progress, serves as another key
downstream signaling molecule for AMPK. AMPK activation promotes
autophagy by directly activating ULK1 through phosphorylation of
Ser317 and Ser777. To the contrary, high mTOR activity prevents ULK1
activation by phosphorylating ULK1 at Ser757 to disengage the interac-
tion betweenULK1 andAMPK [53]. Our data revealed that high glucose-
induced AMPK and ULK1 dephosphorylation and FOXO3a phosphoryla-
tion were reversed by ALDH2 transgene and Alda-1. These ﬁndings
favor a role of theAMPK signaling in the regulation of ALDH2-elicted au-
tophagic responses in diabetic-induced toxicity. Likewise, in vitro high
glucose incubation suppressed autophagy (Atg7 or LC3B II-to-LC3B I
ratio) was attenuated by Alda-1 although such effects were ablated by
the AMPK inhibitor compound C. This is consistent with the ﬁnding
that AMPK inhibition enhanced high glucose-induced autophagy in
cardiomyocytes. These observations favor the notion that ALDH2 trans-
gene may stimulate AMPK phosphorylation en route to dephosphoryla-
tion of FOXO3a and phosphorylation of ULK1, thus favoring promotion
of autophagy in the face of high glucose toxicity. FoxO3a was reported
as a pivotal regulator of autophagy. Activation of the nuclear transcrip-
tional factor with overexpression, dephosphorylation and deacetylation
induces autophagy by activating Atgs in the setting of oxidative stress
[54]. It remains unclear with regard to the precise role of FoxO3a (in
particular post-translational modiﬁcation of such) in different types of
diabetes. Previous research showed that AMPK activation stimulates au-
tophagy in skeletalmuscle cells through its effects on the transcriptional
modiﬁcation of FoxO3a and the initiation of autophagosome formation
by interacting with ULK1 [23]. This dogma received convincing support
from our current experimental ﬁndings. Our data revealed that ALDH2
may rescue against high glucose-induced FOXO3a phosphorylation
and ULK1 inactivation through its upstream signaling molecule AMPK,
resulting in an AMPK-dependent induction of autophagy [55]. Evidence
revealed that ALDH2 signiﬁcantly alters high glucose-induced changes
in the phosphorylation of FOXO3a, favoring autophagy induction [55].
Such regulatorymachinery involvingULK1, FOXO3a and AMPKmay un-
derscore the homeostatic machinery for ALDH2 and Alda-1-elicited
cardioprotection against high glucose-induced toxicity. This is consis-
tent with the ﬁnding that elevation of Alda-1 activity may protect
against ischemic heart and arrhythmic damage [2,9]. Nonetheless,
given the notion that AMPK may regulate FOXO3a and ULK1 mediated
autophagy via anAMPK-dependentmechanism, further scrutiny iswar-
ranted to better illustrate the role of AMPK in diabetes-inducedmyocar-
dial anomalies, the expression of AMPK regulation of autophagy and
subsequently, changes in myocardial function. Acute insulin deﬁciency
(STZ-induced diabetes) and high glucose decreased phosphorylation
of Foxo3a as shown in our previous report (BMC Med 2012), which
are expected to promote autophagy. Nonetheless, data presented in
our current work depicted that prolonged duration of diabetes and ex-
posure of high glucose rather increased the phosphorylation of Foxo3a
and in consequence attenuated autophagosome formation. Such dis-
crepancy suggests that duration of diabetes or high glucose exposure
may present as a dynamic regulatory factor and thus contribute to the
ultimate outcome of autophagy.
In summary, ﬁndings from our study have provided convincing evi-
dence that ALDH2 rescues against diabetes-induced cardiac mechanical
and geometric defects, intracellular Ca2+ dysregulation and apoptosis
through regulation of autophagy. ALDH2 and its activator Alda-1 offer
their beneﬁcial responses through preserved phosphorylation of
AMPK and subsequently, dephosphorylation of FOXO3a. Further study
is warranted to unveil the impact of ALDH2 on autophagy in the more
clinically relevant condition of cardiomyocyte injury onset and some
therapeutic promise of diabetic complications.
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